Matrix metalloproteinase inhibitors
- 1 October 1997
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 7 (10) , 1213-1216
- https://doi.org/10.1517/13543776.7.10.1213
Abstract
In these three closely related patent applications, Chiroscience discloses a series of di- and tri-peptidyl compounds containing an α-mercaptoacyl zinc binding group as well as a series of peptidyl compounds lacking the thiol group. The compounds are claimed to be inhibitors of matrix metalloproteinases (MMPs) and of tumour necrosis factor-α (TNF-α) release and, as such, are claimed to be of therapeutic value in a wide range of diseases such as rheumatoid arthritis, osteoarthritis and cancer metastasis or invasion. The current applications contain no in vitro or in vivo data to support any of the above claims.Keywords
This publication has 5 references indexed in Scilit:
- Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in RabbitsJournal of Medicinal Chemistry, 1997
- Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase InhibitorsCurrent Pharmaceutical Design, 1997
- A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disordersBioorganic & Medicinal Chemistry Letters, 1997
- Inhibition of Matrix Metalloproteinases: Structure Based DesignCurrent Pharmaceutical Design, 1996
- Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Inhibitors of TNFα synthesisExpert Opinion on Therapeutic Patents, 1995